Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies

BACKGROUND: Cancer patients are more vulnerable to COVID-19 and are thus given high priority in vaccination campaigns. In solid cancer patients treated with checkpoint inhibitors, we evaluated the amount of anti-RBD and neutralizing antibodies and antibody avidity after two or three doses of the vac...

Descripción completa

Detalles Bibliográficos
Autores principales: Caruso, Teresita, Salani, Francesca, Catanese, Silvia, Pratesi, Federico, Mercinelli, Chiara, Motta, Giuseppe, Genovesi, Virginia, Bonato, Adele, Sara, Galimberti, Masi, Gianluca, Migliorini, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869844/
https://www.ncbi.nlm.nih.gov/pubmed/36689013
http://dx.doi.org/10.1007/s10147-023-02295-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869844/
https://www.ncbi.nlm.nih.gov/pubmed/36689013
http://dx.doi.org/10.1007/s10147-023-02295-0

Ejemplares similares